{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04175431",
            "orgStudyIdInfo": {
                "id": "RG1004972"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2019-07437",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "10349",
                    "type": "OTHER",
                    "domain": "Fred Hutch/University of Washington Cancer Consortium"
                }
            ],
            "organization": {
                "fullName": "University of Washington",
                "class": "OTHER"
            },
            "briefTitle": "Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study",
            "officialTitle": "Prostate Specific Membrane Antigen (PSMA) or Fluciclovine (FACBC) PET/CT Site-Directed Therapy of OLigometASTatic Prostate Cancer (P-Flu-BLAST-PC): A Multicenter Study",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "prostate-specific-membrane-antigen-psma-or-facbc-pet-ct-site-directed-therapy-for-treatment-of-prostate-cancer-flu-blast-pc-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-09-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-07-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-07-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-11-07",
            "studyFirstSubmitQcDate": "2019-11-20",
            "studyFirstPostDateStruct": {
                "date": "2019-11-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Washington",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Blue Earth Diagnostics",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.",
            "detailedDescription": "OUTLINE: Patients are assigned to 1 of 3 groups.\n\nGROUP I: Patients for whom initial fluciclovine or PSMA PET/CT does not reveal any abnormalities outside the prostatic fossa undergo PSA rechecks every 3 months, and undergo fluciclovine or PSMA PET/CT once PSA is \\> 2 ng/ml. If still no abnormalities are found outside of the prostatic fossa, patients continue to undergo PSA rechecks every 3 months, and undergo fluciclovine or PSMA PET/CT once PSA is \\> 5 ng/ml. Patients are off study for treatment plan once PSA reaches 10 ng/ml.\n\nGROUP II: Patients undergo fluciclovine or PSMA PET/CT and who have =\\< 3 regions of metastatic disease outside of the prostatic fossa that are amenable to metastasis-directed therapy undergo lymphadenectomy or radiation therapy. Six to ten weeks after surgery, patients receive abiraterone acetate 1000 mg orally (PO) once daily (QD) and prednisone PO QD. Treatment repeats every 4 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may start radiation therapy after 2 cycles of abiraterone acetate and prednisone.\n\nGROUP III: Patients undergo fluciclovine or PSMA PET/CT and who have \\> 3 regions of metastatic disease receive abiraterone acetate and prednisone as in Group II.\n\nAfter completion of study treatment, patients are followed up at 37, 49, 61, 73, 85, 97, 109, and 121 weeks, at 36, 42, 48, 54, 60, and 66 months, and then annually thereafter."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Adenocarcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group I (fluciclovine PET/CT)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Patients for whom initial fluciclovine or PSMA PET/CT does not reveal any abnormalities outside the prostatic fossa undergo PSA rechecks every 3 months, and undergo fluciclovine or PSMA PET/CT once PSA is \\> 2 ng/ml. If still no abnormalities are found outside of the prostatic fossa, patients continue to undergo PSA rechecks every 3 months, and undergo fluciclovine or PSMA PET/CT once PSA is \\> 5 ng/ml. Patients are off study for treatment plan once PSA reaches 10 ng/ml.",
                    "interventionNames": [
                        "Procedure: Positron Emission Tomography",
                        "Procedure: Computed Tomography",
                        "Procedure: PSMA PET Scan"
                    ]
                },
                {
                    "label": "Group II (surgery, radiotherapy, abiraterone, prednisone)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients undergo fluciclovine or PSMA PET/CT and who have =\\< 3 regions of metastatic disease outside of the prostatic fossa that are amenable to metastasis-directed therapy undergo lymphadenectomy or radiation therapy. Six to ten weeks after surgery, patients receive abiraterone acetate 1000 mg PO QD and prednisone PO QD. Treatment repeats every 4 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may start radiation therapy after 2 cycles of abiraterone acetate and prednisone.",
                    "interventionNames": [
                        "Procedure: Positron Emission Tomography",
                        "Procedure: Lymphadenectomy",
                        "Radiation: Radiation Therapy",
                        "Drug: Abiraterone Acetate",
                        "Drug: Prednisone",
                        "Procedure: Computed Tomography",
                        "Drug: Abiraterone",
                        "Procedure: PSMA PET Scan"
                    ]
                },
                {
                    "label": "Group III (abiraterone, prednisone)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients undergo fluciclovine or PSMA PET/CT and who have \\> 3 regions of metastatic disease receive abiraterone acetate and prednisone as in Group II.",
                    "interventionNames": [
                        "Procedure: Positron Emission Tomography",
                        "Drug: Abiraterone Acetate",
                        "Drug: Prednisone",
                        "Procedure: Computed Tomography",
                        "Drug: Abiraterone",
                        "Procedure: PSMA PET Scan"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Positron Emission Tomography",
                    "description": "Undergo fluciclovine PET/CT",
                    "armGroupLabels": [
                        "Group I (fluciclovine PET/CT)",
                        "Group II (surgery, radiotherapy, abiraterone, prednisone)",
                        "Group III (abiraterone, prednisone)"
                    ],
                    "otherNames": [
                        "Medical Imaging",
                        "PET Scan",
                        "positron emission tomography scan",
                        "proton magnetic resonance spectroscopic imaging",
                        "Positron-Emission Tomography"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Lymphadenectomy",
                    "description": "Undergo lymphadenectomy",
                    "armGroupLabels": [
                        "Group II (surgery, radiotherapy, abiraterone, prednisone)"
                    ],
                    "otherNames": [
                        "Lymph Node Dissection",
                        "lymph node excision",
                        "excision of the lymph node"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "Radiation Therapy",
                    "description": "Undergo radiation therapy",
                    "armGroupLabels": [
                        "Group II (surgery, radiotherapy, abiraterone, prednisone)"
                    ],
                    "otherNames": [
                        "Cancer Radiotherapy",
                        "Irradiation",
                        "Radiotherapeutics",
                        "RT",
                        "ENERGY_TYPE",
                        "Irradiated",
                        "Therapy, Radiation",
                        "NOS"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Abiraterone Acetate",
                    "description": "Given PO",
                    "armGroupLabels": [
                        "Group II (surgery, radiotherapy, abiraterone, prednisone)",
                        "Group III (abiraterone, prednisone)"
                    ],
                    "otherNames": [
                        "154229-18-2",
                        "Yonsa",
                        "Zytiga",
                        "Androsta-5"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Prednisone",
                    "description": "Given PO",
                    "armGroupLabels": [
                        "Group II (surgery, radiotherapy, abiraterone, prednisone)",
                        "Group III (abiraterone, prednisone)"
                    ],
                    "otherNames": [
                        "Deltasone",
                        "Prednicort",
                        "Prednisone Intensol",
                        "Rayos",
                        "Sterapred",
                        "Dehydrocortisone",
                        "Prednilonga",
                        "Servisone"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Computed Tomography",
                    "description": "Undergo fluciclovine PET/CT",
                    "armGroupLabels": [
                        "Group I (fluciclovine PET/CT)",
                        "Group II (surgery, radiotherapy, abiraterone, prednisone)",
                        "Group III (abiraterone, prednisone)"
                    ],
                    "otherNames": [
                        "CAT Scan",
                        "CAT",
                        "computerized axial tomography",
                        "computerized tomography",
                        "CT Scan"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Abiraterone",
                    "description": "Given PO",
                    "armGroupLabels": [
                        "Group II (surgery, radiotherapy, abiraterone, prednisone)",
                        "Group III (abiraterone, prednisone)"
                    ],
                    "otherNames": [
                        "154229-19-3",
                        "17-(3-Pyridyl)androsta-5",
                        "16-dien-3beta-ol",
                        "CB 7598"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "PSMA PET Scan",
                    "description": "Undergo PSMA PET scan",
                    "armGroupLabels": [
                        "Group I (fluciclovine PET/CT)",
                        "Group II (surgery, radiotherapy, abiraterone, prednisone)",
                        "Group III (abiraterone, prednisone)"
                    ],
                    "otherNames": [
                        "Prostate-specific Membrane Antigen PET",
                        "PSMA PET",
                        "PSMA-Positron emission tomography"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Undetectable PSA (< 0.2 ng/mL) rate",
                    "timeFrame": "At 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Total testosterone",
                    "timeFrame": "Up to 7 years"
                },
                {
                    "measure": "Median time to reinitiation of antiandrogen therapy (ADT)",
                    "timeFrame": "Up to 7 years"
                },
                {
                    "measure": "Overall survival",
                    "timeFrame": "Up to 7 years"
                },
                {
                    "measure": "Number of patients with abnormalities within the prostatic fossa with PSA < 10 ng/mL",
                    "timeFrame": "Up to 7 years"
                },
                {
                    "measure": "Number of patients without abnormalities with PSA < 10 ng/mL",
                    "timeFrame": "Up to 7 years"
                },
                {
                    "measure": "Number of patients with PSA < 10 mg/mL and > 3 regions of metastatic prostate cancer on fluciclovine PET/CT",
                    "timeFrame": "Up to 7 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient must have histologically or cytologically documented evidence of prostate adenocarcinoma\n* Patient must previously have undergone radical prostatectomy\n* Patient must previously have undergone either adjuvant or salvage radiation therapy to the prostatic fossa +/- whole pelvis\n* Patient must have a prostate specific antigen (PSA) \\>= 0.2 and \\< 10 ng/mL. If there is only one PSA value that has risen to \\>= 0.2 with this biochemical recurrence, a second PSA value must be confirmed to be within \\>= 0.2 and \\< 10 ng/mL at least 2 weeks from the first value and within 28 days of enrollment\n* PSA doubling time must be calculated utilizing either all PSA measurements \\> 0.1 ng/mL from most recent biochemically-recurred (BCR) or the most recent 3 PSA measurements \\> 0.1 ng/mL (if the latter, all 3 PSA measurements must be \\> 2 weeks apart to be used in the calculation). PSA doubling time must be \\> 3 months and \\< 18 months. The Memorial Sloan Kettering PSA doubling time calculator should be used\n* Patient must have no previous evidence of radiographically detectable metastatic prostate cancer by conventional CT and bone scan imaging\n* Patient must have total testosterone level \\> 120 ng/dL demonstrated within 42 days of enrollment\n* Patient must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Absolute neutrophil count (ANC) \\>= 1.0 X 10\\^9/L\n* Platelet count \\>= 100 X 10\\^9/L\n* Hemoglobin \\>= 9 g/dL\n* Potassium \\>= 3.5\n* Serum bilirubin =\\< 1.5 X upper limit of normal (ULN) or =\\< 3 X ULN for patients with documented Gilbert's syndrome\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\< 3 X ULN\n* Creatinine clearance (Cr Cl) \\>= 30 mL/min as estimated by the Cockcroft-Gault criteria or as determined by 24 hour Cr Cl measurement\n* Patient must be \\>= 18 years of age on day of signing informed consent\n* Patient must be able to understand and authorize informed consent\n\nExclusion Criteria:\n\n* Chronic active hepatitis B or C\n* History of a second, non-prostate malignancy that required systemic therapy in the last 2 years except cancer in situ of bladder and non-melanomatous cancers of the skin\n* Patient with a serious underlying medical condition that would otherwise impair the patient's ability to undergo fluciclovine or PSMA PET/CT imaging or receive subsequent treatment\n* Any condition that would alter the patient's mental status, prohibiting understanding and/or authorization of informed consent\n* Expected lifespan of less than 12 weeks\n* Inability to lay still for imaging\n* Weight \\> 300 lbs. (due to equipment specifications)\n* Any other underlying medical condition that, in the opinion of the investigator, would impair the ability of the patient to receive or tolerate the planned treatment and/or follow up",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Patrick Panlasigui",
                    "role": "CONTACT",
                    "phone": "206-606-7486",
                    "email": "ppanlas2@fredhutch.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Evan Yu",
                    "affiliation": "Fred Hutch/University of Washington Cancer Consortium",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Pittsburgh Cancer Institute (UPCI)",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Risa Wong",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Fred Hutch/University of Washington Cancer Consortium",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Patrick Panlasigui",
                            "role": "CONTACT",
                            "phone": "206-606-7486",
                            "email": "ppanlas2@fredhutch.org"
                        },
                        {
                            "name": "Evan Yu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10295",
                    "name": "Influenza, Human",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011241",
                    "term": "Prednisone"
                },
                {
                    "id": "D000069501",
                    "term": "Abiraterone Acetate"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14121",
                    "name": "Prednisone",
                    "asFound": "Prospective",
                    "relevance": "HIGH"
                },
                {
                    "id": "M451",
                    "name": "Abiraterone Acetate",
                    "asFound": "Unilateral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}